The MHRA identified several inspection responses generated by artificial intelligence. This UK medicines regulator now demands transparency when firms use AI to draft GxP compliance submissions. Practitioners must ensure human oversight of all technical data. Failure to disclose AI usage risks regulatory friction and potential rejection of critical compliance documentation.